A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
Phase of Trial: Phase I/II
Latest Information Update: 13 May 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Bevacizumab (Primary)
- Indications Keratoplasty rejection
- Focus Adverse reactions; Therapeutic Use
- 09 May 2019 Status changed from active, no longer recruiting to completed.
- 04 Oct 2018 Planned End Date changed from 1 Sep 2018 to 1 Dec 2019.
- 04 Oct 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2019.